Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
22 4월 2020 - 12:31AM
Business Wire
Collaboration to Advance Cancer Genomics
Insights to Enable Novel Discoveries
Indivumed GmbH (“Indivumed”) and Personalis, Inc. (Nasdaq: PSNL)
today announced that the two companies have entered into a
collaboration in the field of personalized oncology. The
partnership seeks to enable novel discoveries in cancer biology by
pairing IndivuType, Indivumed’s multiomics cancer database, with
genome and transcriptome-level data from thousands of samples using
Personalis’ advanced cancer genomics technology.
“Genomics and transcriptomics play a crucial role in truly
understanding cancer biology,” said Dr. Hartmut Juhl, Indivumed CEO
and founder. “Adding Personalis’ technology to the IndivuType
multiomics profile will enable relevant discoveries in our
collaborations with pharma and biotech and further our mission to
advance precision oncology.”
The IndivuType database provides high-quality samples that
enable analysis beyond genomics to include transcriptomics,
proteomics, phosphoproteomics and immunophenotyping in combination
with clinical and outcome data that makes it a powerful resource
for the cancer community. Pairing these high-quality samples with
Personalis’ innovative and robust solutions for comprehensive tumor
genomics characterization has the potential to provide deeper
insights into oncology therapeutics.
“Working with Indivumed on this program will allow us to deliver
broad, more comprehensive genomic sequencing for cancer that can
ultimately fuel drug discovery and development,” said John West,
CEO of Personalis. “Pairing Indivumed’s leading position as a
premier quality clinical cancer biobank with our extensive genomics
experience will result in one of the most comprehensive multiomics
cancer databases in the world. More importantly we feel these
databases will provide the insights needed to drive precision
medicine in oncology. This new offering leverages Personalis’
extensive whole genome sequencing experience, including laboratory
automation and data systems developed for the U.S. Department of
Veterans Affairs (“VA”) Million Veterans Program, and our expertise
in processing tumor samples as part of large-scale oncology
translational research projects with our biopharma partners.”
About Indivumed
Indivumed is a science-led, integrated global oncology company.
The Indivumed platform is an enabler for the next generation of
precision oncology through Indivumed’s proprietary multiomics
cancer database and customized data analytics, underpinned by
Indivumed’s global network of affiliated clinics with gold-standard
quality of biospecimens. Through Indivumed’s unique platform,
Indivumed offers specialized products and services that support our
customers in biomarker and target discovery, drug development,
clinical trials, individualized therapy and more. More information
at www.indivumed.com.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis ImmunoID NeXT Platform™
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. For
example, forward-looking statements include statements regarding
potential positive outcomes resulting from the collaboration of
Personalis and Indivumed, such as the ability of the collaboration
to yield novel discoveries. These forward-looking statements are
subject to risks and uncertainties, including those discussed in
Personalis’ filings with the Securities and Exchange Commission
(SEC), including in the “Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations”
sections of the Company’s most recently filed periodic report on
Form 10-K and subsequent filings and in the documents incorporated
by reference therein. Except as otherwise required by law,
Personalis disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date hereof, whether as a result of new information, future events
or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200421005642/en/
Contact for Indivumed: Patrick Renegar W: 703-519-1600
Ext. 104 prenegar@livewiredc.com
Contacts for Personalis,
Inc. Investor Relations Contact for Personalis:
Caroline Corner investors@personalis.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024